Αποτελέσματα Αναζήτησης
Clinical and radiological prognostic factors only partially change the progression-free survival but they do not improve the overall survival. Despite efforts, there is currently no curative therapy for DMG. Radiotherapy remains the standard treatment with only transitory benefits.
19 Νοε 2022 · Diffuse midline glioma (DMG), formerly called diffuse intrinsic pontine glioma (DIPG), is a high-grade malignant pediatric brain tumor with a near-zero survival rate. To date, only radiation therapy provides marginal survival benefit; however, the median survival time remains less than a year.
6 Απρ 2023 · Diffuse midline glioma (DMG) is the leading cause of brain tumor-related deaths in children. DMG typically presents with variable neurologic symptoms between ages 3 and 10. Currently, radiation remains the standard therapy for DMG to halt progression and reduce tumor bulk to minimize symptoms.
3 Νοε 2023 · Attempts at increasing tumor cell kill using higher total doses of radiation, hyperfractionated radiotherapy, and/or radiation sensitizers as initial therapy have not resulted in improved outcomes [15, 16, 17]. Tumor resistance is a common concern for patients with DMG.
16 Απρ 2024 · From a radiation therapy treatment planning perspective, clinical target volume (CTV) margins for DIPG and DMG generally add an anatomically constrained 1 to 2 cm expansion to the gross tumor volume (GTV).
21 Ιουν 2024 · Apatinib plus temozolomide could be an effective regimen with manageable toxicities and favorable efficacy and may outperform temozolomide monotherapy, particularly in newly diagnosed adults with tumors located outside the pons. The novel therapy deserves further investigation in adult DMG patients. Key points.
12 Απρ 2023 · Diffuse midline glioma (DMG) is a pediatric cancer that originates in the midline structures of the brain. Prognosis of DMG patients remains poor due to the infiltrative nature of these tumors and the protection they receive from systemically delivered therapeutics via an intact blood–brain barrier (BBB), making treatment difficult.
